Tanespimycin Production Cost Analysis 2020
Tanespimycin, also known as 17-N-allylamino-17-demethoxygeldanamycin or 17-AAG, is a derivative of the antibiotic geldanamycin, which is used while studying the treatment of cancer, particularly in the younger patients with certain types of leukaemia or solid tumours, especially the kidney tumours. It belongs to the family of drugs, which are better known as antitumor antibiotics. It is a less toxic analogue as compared to geldanamycin.
Tanespimycin is an antineoplastic agent and an apoptosis inducer. It has been developed to treat multiple cancer types, chronic myelogenous leukemia, and solid tumours. It works by inhibiting HSP90, which is expressed in those tumours. HSP90 helps keep many oncogenic signalling proteins stable, along with maintaining their functional shape. These maybe overexpressed in tumour cells; thus, by inhibiting HSP90, tanespimycin encourages its proteasomal degradation.
Procurement Resource provides an in-depth cost analysis of Tanespimycin production. The report incorporates the manufacturing process with detailed process and material flow, capital investment, operating costs along with financial expenses and depreciation charges. The study is based on the latest prices and other economic data available. We also offer additional analysis of the report with detailed breakdown of all cost components (Capital Investment Details, Production Cost Details, Economics for another Plant Location, Dynamic Cost Model).